{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:25:22Z","timestamp":1793805922596,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.07.002","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:38:18Z","timestamp":1784806698000},"page":"233-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Circulating KIM-1 and survival outcomes in renal cell carcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"44","author":[{"given":"Jiafu","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8673-087X","authenticated-orcid":false,"given":"Jinhai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10451","key":"10.1016\/j.urolonc.2026.07.002_bib0001","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","article-title":"Renal cell carcinoma","volume":"404","author":"Young","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.002_bib0002","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.euo.2018.08.023","article-title":"Clinical stage migration and survival for renal cell carcinoma in the United States","volume":"2","author":"Patel","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.07.002_bib0003","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1470-2045(07)70173-0","article-title":"TNM staging system for renal-cell carcinoma: current status and future perspectives","volume":"8","author":"Ficarra","year":"2007","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.07.002_bib0004","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.07.002_bib0005","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.3390\/ijms26073431","article-title":"Kidney injury molecule-1 as a biomarker for renal cancer: current insights and future perspectives: a narrative review","volume":"26","author":"Puia","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.urolonc.2026.07.002_bib0006","doi-asserted-by":"crossref","first-page":"64","DOI":"10.17691\/stm2021.13.3.08","article-title":"Kidney Injury molecule 1 (KIM-1): a multifunctional glycoprotein and biological marker (Review)","volume":"13","author":"Karmakova","year":"2021","journal-title":"Sovrem Tekhnologii Med"},{"issue":"3","key":"10.1016\/j.urolonc.2026.07.002_bib0007","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.euf.2025.06.012","article-title":"KIM-1 as a prognostic marker in renal cell carcinoma","volume":"11","author":"Steiner","year":"2025","journal-title":"Eur Urol Focus"},{"issue":"9","key":"10.1016\/j.urolonc.2026.07.002_bib0008","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s11255-025-04447-9","article-title":"Liquid-based kidney injury molecule-1 as a diagnostic and prognostic indicator in renal cell carcinoma: a systematic review and meta-analysis","volume":"57","author":"He","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urolonc.2026.07.002_bib0009","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.urolonc.2026.07.002_bib0010","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.07.002_bib0011","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1200\/JCO.2025.43.16_suppl.4510","article-title":"Genomic characterization of baseline and post-progression tumors in IMmotion010, a randomized, phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with high-risk localized renal cell carcinoma (RCC)","volume":"43","author":"Pal","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6_Suppl","key":"10.1016\/j.urolonc.2026.07.002_bib0012","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1158\/1538-7445.AM2024-5151","article-title":"High serum kidney injury marker-1 and high baseline tumor PD-L1 protein expression levels are independently associated with treatment effect in adjuvant nivolumab plus ipilimumab vs placebo in localized clear cell renal cell carcinoma","volume":"84","author":"Vemula","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2026.07.002_bib0013","first-page":"A75","article-title":"Integrative biomarkers analysis from the phase 3 CheckMate 914 trial of nivolumab plus ipilimumab or nivolumab versus placebo for adjuvant clear cell renal cell carcinoma (ccRCC)","volume":"12","author":"Vemula","year":"2024","journal-title":"J ImmunoTher Cancer"},{"issue":"5_suppl","key":"10.1016\/j.urolonc.2026.07.002_bib0014","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2025.43.5_suppl.437","article-title":"Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): post-hoc analysis of CheckMate 214","volume":"43","author":"Xu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.1574","article-title":"1471P Plasma KIM-1 for preoperative identification and risk stratification of renal cell carcinoma","volume":"33","author":"Xu","year":"2022","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.07.002_bib0016","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1200\/JCO.2024.42.16_suppl.4506","volume":"42","author":"Albiges","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.07.002_bib0017","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1200\/JCO.2025.43.16_suppl.4546","article-title":"Integrative clinical, genomic, and transcriptomic characterization of circulating KIM-1 in metastatic RCC","volume":"43","author":"Machaalani","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"10.1016\/j.urolonc.2026.07.002_bib0018","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2025.43.5_suppl.594","article-title":"KIM-1 as a circulating biomarker in metastatic RCC: post-hoc analysis of JAVELIN Renal 101","volume":"43","author":"Machaalani","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"10.1016\/j.urolonc.2026.07.002_bib0019","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.2025.43.5_suppl.584","article-title":"The role of circulating kidney injury molecule-1 (KIM-1) in metastatic renal cell carcinoma (mRCC): a biomarker analysis of Tide-A, a phase 2 study of first-line avelumab (ave) plus intermittent axitinib (axi)","volume":"43","author":"Ciccarese","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.07.002_bib0020","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1158\/1078-0432.CCR-21-0025","article-title":"Plasma KIM-1 is associated with recurrence risk after nephrectomy for localized renal cell carcinoma: a trial of the ECOG-ACRIN Research Group (E2805)","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.urolonc.2026.07.002_bib0021","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.23.00699","article-title":"Plasma kidney injury molecule-1 for preoperative prediction of renal cell carcinoma versus benign renal masses, and association with clinical outcomes","volume":"42","author":"Xu","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.002_bib0022","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1093\/oncolo\/oyaf276.006","article-title":"Integrative clinical, genomic, transcriptomic, and immunopathologic characterization of circulating KIM-1 in metastatic RCC","volume":"30","author":"Machaalani","year":"2025","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.urolonc.2026.07.002_bib0023","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.annonc.2025.08.007","article-title":"Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma","volume":"36","author":"Rini","year":"2025","journal-title":"Ann Oncol"},{"issue":"5_suppl","key":"10.1016\/j.urolonc.2026.07.002_bib0024","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1200\/JCO.2025.43.5_suppl.582","article-title":"Circulating kidney injury molecule-1 (KIM-1) in association with kidney injury biomarkers and outcomes in metastatic renal cell carcinoma","volume":"43","author":"Steiner","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.002_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2026.03.005","article-title":"KIM-1 in advanced papillary and clear cell renal cell carcinoma","author":"Coca Membribes","year":"2026","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.002_bib0026","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.eururo.2026.01.004","article-title":"KIM-1 and circulating tumor DNA are prognostic markers for oligometastatic clear-cell renal cell carcinoma: development of a multivariable prognostic model","volume":"89","author":"Tang","year":"2026","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.07.002_bib0027","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1681\/ASN.2007030325","article-title":"Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region","volume":"18","author":"Zhang","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.002_bib0028","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2486592","article-title":"Elevated circulating IL-8 correlates with poor prognosis in urological cancers: a meta-analysis and bioinformatic validation","volume":"57","author":"Lin","year":"2025","journal-title":"Ann Med"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:26:43Z","timestamp":1793802403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1078143926005958"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating KIM-1 and survival outcomes in renal cell carcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}